{"nct_id":"NCT05005403","title":"Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab","status":"RECRUITING","status_verified_date":"2025-09","start_date":"2021-11-01","start_date_type":"ACTUAL","primary_completion_date":"2026-07","primary_completion_date_type":"ESTIMATED","completion_date":"2027-06","completion_date_type":"ESTIMATED","phases":["PHASE1"],"tickers":["ABBV"]}